Sign in

NCT02487992Active, not recruitingPhase 2

The Study of CIK Plus S-1 and Bevacizumab as Maintenance Treatment for Patients With Advanced Colorectal Cancer

The Randomized, Controlled, Multicenter Clinical Trial of CIK Plus S-1 and Bevacizumab as Maintenance Treatment for Patients With Advanced Colorectal Cancer

Source: ClinicalTrials.gov · Last updated 24 Feb 2016

Brief summary (registry, in English)

The purpose of this study is to evaluate the safety and efficacy of cytokine-induced killer cell (CIK) plus S-1 and Bevacizumab vs S-1 and Bevacizumab as Maintenance Treatment for patients with advanced colorectal cancer.

Status (registry)
Active, not recruiting
Phase (registry)
Phase 2
Study type
Interventional
Enrollment
1200 (estimated)
First submitted
30 Jun 2015
Start date
1 Jul 2015
Primary completion date
31 Jul 2043
Lead sponsor
The First People's Hospital of Changzhou
NCT number
NCT02487992

What you commit to

  • Study type: Interventional · Phase 2
  • Planned participants: 1200
  • From 1 Jul 2015 to the primary completion date, 31 Jul 2043
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Known or suspected allergy to the investigational agent or any agent given in association with this trial

Other illness

  • Known history of Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV) or TreponemaPallidun (TP) infection
  • Patients who are suffering from serious autoimmune disease
  • Patients who had active infection
  • Patients who are suffering from other cancer

Lab values

  • Hemoglobin\<8.0 g/dL,White blood cell \<3 X 10\^9/L;Platelet count \<75 X 10\^9/L; alanine aminotransferase, glutamic-oxalacetic transaminase, blood urine nitrogen and creatinine more than normal limits on 3.0 times

Other

  • Pregnant or lactating patients
  • Patients who had used long time or are using immunosuppressant
  • Patients who are suffering from serious organ dysfunction
  • Other situations that the researchers considered unsuitable for this study.

Who the study is looking for

  • Patients who can accept curative operations 18-70 years old
  • Histologically confirmed with colorectal cancer at stage Ⅳ
  • Patients who can accept oral drugs;
  • Eastern Cooperative Oncology Group (ECOG) performance status was 0 - 1.

Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.